Posted by bodhisattva_guy on February 4, 2011, at 23:40:18
In reply to Re: New antidepressant just approved. Vilazodone, posted by Cecilia on January 29, 2011, at 1:47:19
Where are you guys getting false info that this medication impacts dopamine receptors?
Please, do not jump to share your knowledge (as helpful as it is to others) until you are sure it is valid. Do not take it personally - just read up more before posting.Here is an excerpt from quite detailed article about this drug's development and psycho pharmacological profile. It points out that no dopamine receptors are activated by this drug, while also clearing up some other misstatements.
TommyYou can view the pdf version here:
www.biomedcentral.com/content/pdf/cd-768430.pdfor plain html here:
http://webcache.googleusercontent.com/search?q=cache:I7q1-RMGx5YJ:www.biomedcentral.com/content/pdf/cd-768430.pdf+vilazodone+receptors+dopamine&hl=en&gl=usStructural modifications of this series to
maximize affinity for both the serotonin transporter and the
5-HT1A receptor, and to minimize affinity for dopamine
receptors, resulted in the creation of vilazodone [741693].
Thus, vilazodone was designed specifically to have potent
dual activity both as an SSRI and a 5-HT1A receptor agonist
without interaction with other neurotransmitter transporters
or receptors, thereby reducing side effect liability [245884].
Originally developed by Merck KGaA and later by
GlaxoSmithKline plc [399224], vilazodone is licensed to
Genaissance Pharmaceuticals Inc (a subsidiary of Clinical
Data Inc), which is currently developing this agent via
Precigen Therapeutics Inc (another subsidiary of Clinical
Data) [627525], [667315
poster:bodhisattva_guy
thread:977653
URL: http://www.dr-bob.org/babble/20110130/msgs/978672.html